BioVie Inc. (NASDAQ:BIVI) Short Interest Down 16.2% in April

BioVie Inc. (NASDAQ:BIVI) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 129,231 shares, a decline of 16.2% from the March 31st total of 154,206 shares. Based on an average daily trading volume, of 55,969 shares, the short-interest ratio is presently 2.3 days. Approximately 1.7% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioVie in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

BioVie Trading Up 1.8%

Shares of BIVI traded up $0.03 during trading hours on Friday, reaching $1.68. 217,449 shares of the company traded hands, compared to its average volume of 70,022. The stock’s fifty day moving average price is $1.41 and its 200 day moving average price is $1.42. The firm has a market cap of $12.67 million, a price-to-earnings ratio of -0.52 and a beta of 0.72. BioVie has a 12-month low of $1.06 and a 12-month high of $13.20.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings results on Friday, February 6th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.04.

Institutional Trading of BioVie

Several institutional investors and hedge funds have recently modified their holdings of BIVI. XTX Topco Ltd bought a new position in BioVie in the fourth quarter worth approximately $25,000. Two Sigma Investments LP bought a new stake in BioVie during the 3rd quarter valued at $62,000. Squarepoint Ops LLC purchased a new stake in shares of BioVie in the 3rd quarter worth $63,000. NewEdge Advisors LLC lifted its holdings in shares of BioVie by 283.7% in the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock worth $53,000 after buying an additional 40,000 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of BioVie during the 2nd quarter worth $57,000. Institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.